Efficacy of high-dose intralesional triamcinolone for hidradenitis suppurativa.
Journal
International journal of dermatology
ISSN: 1365-4632
Titre abrégé: Int J Dermatol
Pays: England
ID NLM: 0243704
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
05
05
2020
revised:
20
06
2020
accepted:
15
07
2020
pubmed:
19
8
2020
medline:
22
6
2021
entrez:
19
8
2020
Statut:
ppublish
Résumé
Hidradenitis suppurativa (HS) is a chronic inflammatory disorder of hair follicles characterized by recurrent, painful nodules, abscesses, and sinus tracts ("tunnels") typically refractory to treatment. This debilitating condition results in poor quality of life due to high disease burden. Intralesional triamcinolone (ILTAC) is a standard of care for acute inflammation and drainage associated with HS; however, the optimal therapeutic dose has not been determined. We investigated the utility of high-dose ILTAC 20 mg/ml (ILTAC-20) or 40 mg/ml (ILTAC-40), for inflammatory lesions of HS. A retrospective chart review and telephone questionnaire included HS patients treated with high-dose ILTAC-20 or ILTAC-40 between April and December 2018. Patients with Hurley stages I-III were included. Data were obtained from electronic medical records and telephone interviews. A short questionnaire pertained to satisfaction with therapy, changes of disease state, and modifications in quality of life. Of 54 patients interviewed, the average age was 36.9 ± 11.6 years; 36 (66.7%) were female. Forty patients (76.9%) were very satisfied (n = 19) or satisfied (n = 21) with high-dose ILTAC therapy. Fifty patients (92.6%) demonstrated improvements in disease state, and 41 patients (75.9%) experienced enhanced quality of life. Forty-four patients (86.3%) were amenable to additional injections of high-dose ILTAC, if clinically indicated. No adverse effects of therapy were reported. The majority of patients reported improvements in disease state, quality of life, and overall satisfaction after administration of high-dose ILTAC (20-40 mg/ml). These findings support the use of high-dose ILTAC for acute lesions of HS.
Sections du résumé
BACKGROUND
BACKGROUND
Hidradenitis suppurativa (HS) is a chronic inflammatory disorder of hair follicles characterized by recurrent, painful nodules, abscesses, and sinus tracts ("tunnels") typically refractory to treatment. This debilitating condition results in poor quality of life due to high disease burden. Intralesional triamcinolone (ILTAC) is a standard of care for acute inflammation and drainage associated with HS; however, the optimal therapeutic dose has not been determined. We investigated the utility of high-dose ILTAC 20 mg/ml (ILTAC-20) or 40 mg/ml (ILTAC-40), for inflammatory lesions of HS.
METHODS
METHODS
A retrospective chart review and telephone questionnaire included HS patients treated with high-dose ILTAC-20 or ILTAC-40 between April and December 2018. Patients with Hurley stages I-III were included. Data were obtained from electronic medical records and telephone interviews. A short questionnaire pertained to satisfaction with therapy, changes of disease state, and modifications in quality of life.
RESULTS
RESULTS
Of 54 patients interviewed, the average age was 36.9 ± 11.6 years; 36 (66.7%) were female. Forty patients (76.9%) were very satisfied (n = 19) or satisfied (n = 21) with high-dose ILTAC therapy. Fifty patients (92.6%) demonstrated improvements in disease state, and 41 patients (75.9%) experienced enhanced quality of life. Forty-four patients (86.3%) were amenable to additional injections of high-dose ILTAC, if clinically indicated. No adverse effects of therapy were reported.
CONCLUSIONS
CONCLUSIONS
The majority of patients reported improvements in disease state, quality of life, and overall satisfaction after administration of high-dose ILTAC (20-40 mg/ml). These findings support the use of high-dose ILTAC for acute lesions of HS.
Substances chimiques
Triamcinolone
1ZK20VI6TY
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
217-221Informations de copyright
© 2020 the International Society of Dermatology.
Références
Jemec GB. Clinical practice. Hidradenitis suppurativa. N Engl J Med 2012; 366: 158-164.
Smith MK, Nicholson CL, Parks-Miller A, et al. Hidradenitis suppurativa: an update on connecting the tracts. F1000Res 2017; 6: 1272.
Jimenez-Gallo D, de la Varga-Martinez R, Ossorio-Garcia L, et al. The clinical significance of increased serum proinflammatory cytokines, C-reactive protein, and erythrocyte sedimentation rate in patients with Hidradenitis suppurativa. Mediators Inflamm 2017; 2017: 1-8.
Pacific KP, Babbush KM, Johnston A, et al. Erythrocyte Sedimentation rate, C-Reactive Protein, Interleukin-6, and Tumor Necrosis Factor Alpha Levels Predict Hidradenitis Suppurativa Severity. 4th Annual Symposium on Hidradenitis Suppurativa Advances; November 2019; Detroit, MI.
Xu H, Xiao X, He Y, et al. Increased serum interleukin-6 levels in patients with hidradenitis suppurativa. Postepy Dermatol Alergol 2017; 34: 82-84.
Margesson LJ, Danby FW. Hidradenitis suppurativa. Best Pract Res Clin Obstet Gynaecol 2014; 28: 1013-1027.
Woodruff CM, Charlie AM, Leslie KS. Hidradenitis suppurativa: a guide for the practicing physician. Mayo Clin Proc 2015; 90: 1679-1693.
Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: topical, intralesional, and systemic medical management. J Am Acad Dermatol 2019; 81: 91-101.
Álvarez P, García-Martínez FJ, Poveda I, et al. Intralesional triamcinolone for fistulous tracts in Hidradenitis suppurativa: an uncontrolled prospective trial with clinical and ultrasonographic follow-up. Dermatology 2020; 236: 46-51.
Riis PT, Boer J, Prens EP, et al. Intralesional triamcinolone for flares of Hidradenitis Suppurativa (HS): a case series. J Am Acad Dermatol 2016; 75: 1151-1155.
Information NCfB. Triamcinolone CID=31307. Accessed November 19, 2019.
Fajgenbaum K, Crouse L, Dong L, et al. Intralesional triamcinolone may not be beneficial for treating acute Hidradenitis Suppurativa lesions: a double-blind, randomized, placebo-controlled trial. Dermatol Surg 2020; 46: 685-689.
Bellin E, Fletcher DD, Geberer N, et al. Democratizing information creation from health care data for quality improvement, research, and education-the Montefiore Medical Center Experience. Acad Med 2010; 85: 1362-1368.
Garg A, Kirby JS, Lavian J, et al. Sex- and age-adjusted population analysis of prevalence estimates for Hidradenitis Suppurativa in the United States. JAMA Dermatol 2017; 153: 760-764.
Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol 2015; 29: 619-644.
Kouris A, Platsidaki E, Christodoulou C, et al. Quality of life and psychosocial implications in patients with Hidradenitis suppurativa. Dermatology 2016; 232: 687-691.
Machado MO, Stergiopoulos V, Maes M, et al. Depression and anxiety in adults with Hidradenitis Suppurativa: a systematic review and meta-analysis. JAMA Dermatol 2019; 155: 939.
Patel ZS, Hoffman LK, Buse DC, et al. Pain, psychological comorbidities, disability, and impaired quality of life in Hidradenitis Suppurativa [corrected]. Curr Pain Headache Rep 2017; 21: 49.
Callen JP. Intralesional corticosteroids. J Am Acad Dermatol 1981; 4: 149-151.